Status: Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Participants needed: 144
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Engeneic Pty LimitedUpdated: Feb 27, 2026Locations: 4
Eligibility criteria
Histological or pathological confirmation of metastatic pancreas adenocarcinoma.... [+19]
Subjects currently receiving any other investigational agent. [+25]